If not the president, then who, senator asks
— If not the president, then who, senator asks
by Kristina Fiore, Director of Enterprise & Investigative Reporting, MedPage Today
June 25, 2026
• 3 min read
Democratic lawmakers are pressing the Trump administration to disclose who received special access to Eli Lilly's investigational obesity drug retatrutide.
Democrats press White House on who got special access to Eli Lilly’s new obesity drug
Eli Lilly Approved Obesity Drug for Mystery 79-Year-Old Patient
Dems Demand Answers About Whether Trump Received Experimental Weight Loss Drug
Just Who Is the Mystery 79-Year-Old Patient Who Got Special Access to an Experimental Weight Loss Drug?
White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The Presi
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?
Remember That Time Trump Said He “Probably Should” Take Ozempic?
White House denies Trump is the mystery patient who got early access to obesity drug
White House denies Trump was mystery patient given early access to weight-loss drug
Did Trump Get Early Access to Eli Lilly’s New Weight-Loss Drug?
The unusual access to an experimental drug has captured the attention of the American public as well.
Questions are swirling over Donald Trump’s health after a bombshell report revealed a mystery man was getting unprecedented…
The White House denied earlier this week that the president received priority access to an experimental weight loss drug.
The White House has denied that the application was filed on behalf of President Donald Trump.
Compassionate use of retatrutide granted for someone with sleep apnea, pulmonary hypertension
White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide through an FDA program.
